| Name | Title | Contact Details |
|---|
AMBA is a Texas-based insurance broker that provides services such as financial planning, database management and marketing for members.
The Badminton World Federation (BWF) is the international governing body of the sport of badminton, recognised by the International Olympic Committee (IOC) and the International Paralympic Committee (IPC). It was originally the International Badminton Federation (IBF) which was founded on 5 July, 1934, before being rechristened the Badminton World Federation in 2006. The purpose and objectives of BWF include regulating, promoting, developing and popularising the sport of badminton throughout the world and organising, conducting and presenting international events at the highest level. The BWFs vision is to make badminton a leading global sport accessible to all – giving every child a chance to play for life. Its mission is to lead and inspire all stakeholders; to deliver entertainment through exciting events to drive fan experience; and to create innovative, impactful and sustainable development initiatives. BWF has its headquarters in Kuala Lumpur, Malaysia, with 194 Member Associations worldwide. Poul-Erik Høyer is the BWF President and Thomas Lund is the BWF Secretary General.
HPI redefines what is possible with self-funded health plans. As a third-party administrator, we partner with health plan brokers and employers to provide innovative self-funding strategies and customized plans tailored to each clients needs and population. Our solutions give employers greater cost transparency and control, while elevating the member experience.
Taking forward a strong legacy, Pakistan Oxygen is the leading supplier of industrial and medical gases solutions in Pakistan, incorporating our trusted quality and safety standards with superior technology. Our legacies are pioneering and helping our customers grow and surpass new boundaries every day. With the widest range of bulk and compressed gases products, including the ASU gases - Oxygen, Nitrogen and Argon, to the specialty gases and mixtures, along with our range of welding consumables, equipment and safety gear, we are able to serve the needs of our customers, and contribute to the growth and development of our industries by providing them with efficient solutions. At Pakistan Oxygen, customers receive for each gas application, the complete solution – the gas, application knowledge and guidelines, tailor-made hardware and customized services. We have led and contributed to the development of the industry for more than 80 years, supplying gases products and customized services to more than 4,000 customers from a wide spectrum of industries ranging from the chemicals and petrochemicals to steel, food and healthcare sectors and more. Our team of trained and professional staff manages 24-hour operations at ten major industrial locations across the country to support our customers wherever they may be located. Our greatest asset are our people who add positive value to the community every day through their skills and meticulous work. Believing in a culture of innovation, and continuous improvement to realize better ideas, we empower our team and support them in their initiatives to achieve the best solutions. To develop, nurture and value the skills of our people remains at the center of our policy to develop a highly competitive and effective work culture. For more details, please visit our website http://www.pakoxygen.com or contact our Customer Services UAN +92 21 111 262 725
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.